Welcome to our dedicated page for Dermata Therapeutics SEC filings (Ticker: DRMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Dermata Therapeutics, Inc. (DRMA) SEC filings page on Stock Titan aggregates the company’s official U.S. regulatory disclosures, offering a structured view of how this dermatology-focused biotechnology issuer reports its activities. Dermata uses SEC filings to describe progress with its Spongilla technology platform, clinical programs such as XYNGARI™ and DMT410, financing arrangements, and key corporate decisions.
Current and prospective investors can review Form 8-K filings for material events, including press release disclosures about clinical trial data, strategic pivots, financing transactions, and significant agreements. For example, Dermata has filed 8-Ks discussing its corporate updates and financial results, the presentation of Phase 3 STAR-1 acne data, increases to its at-the-market offering capacity, and the termination of a License Agreement with Villani, Inc. related to sponge-based pharmaceutical products.
Annual Form 10-K and quarterly Form 10-Q reports (when available) provide more comprehensive information on Dermata’s business, risk factors, financial statements, and details on its lead programs XYNGARI™ and DMT410. These filings also reference key licensing arrangements, intellectual property, and the company’s shift toward over-the-counter pharmaceutical dermatology products.
On Stock Titan, Dermata’s filings are complemented by AI-powered summaries designed to clarify complex sections of lengthy documents, such as clinical trial descriptions, capital structure changes, and agreement terms. Users can quickly understand the implications of new 8-Ks, 10-Qs, and 10-Ks without reading every page, while still having direct access to the full text filed with the SEC. This page also surfaces information relevant to equity offerings and at-the-market programs, helping readers follow how Dermata funds its dermatology pipeline and OTC initiatives.
Dermata Therapeutics filing: Armistice Capital and Steven Boyd report shared beneficial ownership of 53,910 shares, representing
Dermata Therapeutics — Armistice Capital, LLC and Steven Boyd filed an amendment reporting beneficial ownership of 53,910 shares, representing
The filing explains Armistice Capital is investment manager to Armistice Capital Master Fund Ltd., the direct holder of the shares, and that Mr. Boyd, as managing member, may be deemed to beneficially own the securities. The Master Fund disclaims beneficial ownership due to the Investment Management Agreement. The joint filing is signed by Steven Boyd on
Dermata Therapeutics, Inc. received an amended Schedule 13G/A showing updated ownership by funds tied to Michael Bigger. As of February 9, 2026, Bigger Capital beneficially owned 239,103 shares of common stock, including 200,000 shares issuable upon exercise of pre-funded warrants. District 2 Capital Fund beneficially owned 61,000 shares. Based on 2,835,343 shares outstanding as of January 14, 2026 plus 200,000 pre-funded warrant shares, Bigger Capital and its general partner may be deemed to own 7.88% of the common stock, District 2-related entities 2.01%, and Michael Bigger approximately 9.89%. Large additional warrant positions are excluded due to shareholder approval requirements and 4.99% or 9.99% beneficial ownership limitations. The reporting persons certify the holdings are not for changing or influencing control of Dermata.
Dermata Therapeutics, Inc. filed an 8-K describing a change in its independent registered public accounting firm. On January 30, 2026, the company dismissed Baker Tilly US, LLP as auditor, effective January 31, 2026, following approval by the Audit Committee of the Board of Directors.
Baker Tilly’s audit reports for the years ended December 31, 2024 and 2023 contained no adverse or disclaimed opinions and were not qualified, other than an explanatory paragraph raising substantial doubt about Dermata’s ability to continue as a going concern. The company states there were no disagreements with Baker Tilly and no reportable events during those periods.
On February 2, 2026, the Audit Committee approved the appointment of CBIZ CPAs P.C. as Dermata’s new independent registered public accounting firm. CBIZ CPAs had previously served as Dermata’s auditor from 2016 to 2023, and the company reports no consultations with CBIZ CPAs on accounting or audit matters during 2024, 2023, or through January 31, 2026.
Dermata Therapeutics insider Gerald T. Proehl reports beneficial ownership of 694,576 shares of common stock, representing 19.6% of the company’s outstanding shares as of January 29, 2026. This percentage is based on 3,549,393 shares outstanding on that date.
The stake includes 24 shares and options for 1,763 shares held directly, 79,950 shares and 11 warrant shares held through Proehl Investment Ventures LLC, and 612,828 shares held by certain trusts where he is trustee. Some additional options and warrants are excluded because they do not vest or become exercisable within sixty days or require stockholder approval.
The filing states there have been no purchases or sales of Dermata common stock or related convertible securities by Proehl or entities he controls since the prior amendment filed on January 8, 2026.
Dermata Therapeutics, Inc. filed a resale prospectus covering up to 6,207,730 shares of common stock for selling stockholders. This includes 1,484,312 shares already issued, 537,750 pre-funded warrant shares, 2,022,062 Series C warrant shares, 2,022,062 Series D warrant shares, and 141,544 placement agent warrant shares.
The company will not receive proceeds from share resales but may receive cash if warrants are exercised, at $2.04 per share for the Series C and Series D Warrants and $2.55 for the Placement Agent Warrants. Dermata is pivoting from prescription drugs to over-the-counter dermatology products built on its Spongilla technology, with a planned mid‑2026 launch of a once‑weekly topical acne kit using salicylic acid. A 1‑for‑10 reverse stock split became effective on August 1, 2025, and all share figures reflect this adjustment.
Dermata Therapeutics, Inc. filed a prospectus supplement on January 27, 2026 to increase the maximum aggregate offering amount of its common stock issuable under its existing at-the-market offering program with H.C. Wainwright & Co., LLC by an additional $705,000.
The company previously sold $3,454,390 of common stock under the same Sales Agreement and earlier prospectus supplements. The filing also includes a legal opinion from Lowenstein Sandler LLP covering the additional $705,000 of common stock, which is provided as an exhibit.
DRMA is updating its at-the-market stock offering program to allow additional sales of its common stock with an aggregate offering price of up to $705,000 through H.C. Wainwright & Co. under an existing Form S-3 shelf. This amount is in addition to approximately $3,454,390 of common stock previously sold under earlier prospectus supplements. The filing reflects the limits of General Instruction I.B.6 of Form S-3, which restricts primary offerings to no more than one-third of public float in any 12-month period while public float is below $75.0 million. The company reports a public float of about $7,493,999, based on 2,386,624 shares held by non-affiliates as of January 23, 2026, at a reference price of $3.14 per share, and notes that about $1,792,248 of securities have been sold under these limits in the last twelve months.
Dermata Therapeutics, Inc. is registering up to 6,207,730 shares of common stock for resale by existing investors under a Form S-3 registration statement. These shares include 1,484,312 common shares plus shares issuable upon exercise of 537,750 pre-funded warrants, 2,022,062 Series C warrants, 2,022,062 Series D warrants, and 141,544 placement agent warrants, all issued in a December 29, 2025 private placement. Dermata will not receive proceeds from stockholder resales but would receive cash only if the warrants are exercised, which it plans to use for working capital and general corporate purposes.
The company describes a major strategic shift from prescription dermatology to over-the-counter, science-backed products built on its Spongilla technology, with an initial once-weekly topical acne kit targeted for launch in mid-2026. Dermata also notes a 1-for-10 reverse stock split effective August 1, 2025 and highlights Nasdaq listings for its common stock and public warrants under the symbols “DRMA” and “DRMAW.”